1. The impact of immune recovery and treatment duration on disseminated histoplasmosis consolidation therapy in AIDS patients.
- Author
-
Júnior AMBA, Damasceno LS, Filho AABM, Vidal BFB, Júnior JOSA, Sales PHB, and Leitão TDMJS
- Subjects
- Humans, Male, Female, Adult, Middle Aged, CD4 Lymphocyte Count, Brazil epidemiology, Itraconazole therapeutic use, Itraconazole administration & dosage, Immune Reconstitution, Drug Combinations, Consolidation Chemotherapy, Retrospective Studies, Medication Adherence statistics & numerical data, Recurrence, Duration of Therapy, Treatment Outcome, Follow-Up Studies, Antiretroviral Therapy, Highly Active, Histoplasmosis drug therapy, Histoplasmosis immunology, Antifungal Agents therapeutic use, Antifungal Agents administration & dosage, Acquired Immunodeficiency Syndrome drug therapy, Acquired Immunodeficiency Syndrome complications, Acquired Immunodeficiency Syndrome immunology, Deoxycholic Acid therapeutic use, Deoxycholic Acid administration & dosage, Amphotericin B therapeutic use, Amphotericin B administration & dosage, AIDS-Related Opportunistic Infections drug therapy, AIDS-Related Opportunistic Infections immunology, AIDS-Related Opportunistic Infections microbiology
- Abstract
Introduction: The present study investigated the impact of immune recovery and the duration of antifungal adherence in the consolidation phase of disseminated histoplasmosis (DH) in acquired immune deficiency syndrome (AIDS) patients living in a hyperendemic area in northeastern Brazil., Material and Methods: Sixty-nine patients with DH/AIDS, admitted to the São José Hospital between 2010 and 2015, who continued histoplasmosis consolidation therapy at the outpatient clinic were studied. The follow-up duration was at least 24 months., Results: Sixty-eight patients used itraconazole 200-400 mg/day or amphotericin B deoxycholate weekly during the consolidation phase, and six patients relapsed during follow-up. The overall median duration of consolidation antifungal use was 250 days [IQR 101 - 372]. Antifungal withdrawal by medical decision occurred in 41 patients (70.7 %) after a median of 293 days [IQR 128 - 372] of use; 16 patients discontinued by their own decision, with a median of 106 days [IQR 37 - 244] of therapy; three patients had no information available, and nine continued on AF therapy. The median CD4+ T-cell count in the group without relapse was 248 cells/µL [IQR 115-355] within 6 months after admission; conversely, in the relapse group, the median cell count remained below 100 cells/µL. Irregular adherence to highly active antiretroviral therapy (HAART) was the leading risk factor associated with relapse and death (p< 0.01)., Discussion: The regular use of HAART, combined with immune recovery, proved to be highly effective in preventing relapses in DH/AIDS patients, suggesting that long-term antifungal therapy may not be necessary., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 SFMM. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF